| __timestamp | Bio-Techne Corporation | Celldex Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 106352000 | 101881000 |
| Thursday, January 1, 2015 | 144969000 | 4011000 |
| Friday, January 1, 2016 | 162364000 | 102026000 |
| Sunday, January 1, 2017 | 188462000 | 96171000 |
| Monday, January 1, 2018 | 210850000 | 66449000 |
| Tuesday, January 1, 2019 | 240515000 | 42672000 |
| Wednesday, January 1, 2020 | 255497000 | 42534000 |
| Friday, January 1, 2021 | 298182000 | 3068000 |
| Saturday, January 1, 2022 | 349103000 | 1400000 |
| Sunday, January 1, 2023 | 366887000 | 3008000 |
| Monday, January 1, 2024 | 389335000 |
Unveiling the hidden dimensions of data
In the competitive world of biotechnology, cost efficiency is a critical factor for success. This analysis delves into the cost of revenue trends for Bio-Techne Corporation and Celldex Therapeutics, Inc. from 2014 to 2023. Bio-Techne has demonstrated a consistent upward trajectory, with its cost of revenue increasing by approximately 266% over the decade. In contrast, Celldex's cost of revenue has fluctuated significantly, peaking in 2016 and then declining sharply, with a notable drop of over 97% by 2023.
This stark contrast highlights Bio-Techne's robust growth and operational efficiency, while Celldex's volatility suggests challenges in maintaining cost control. The absence of data for Celldex in 2024 further emphasizes the need for strategic adjustments. As the biotech industry continues to evolve, understanding these financial dynamics is crucial for investors and stakeholders aiming to make informed decisions.
Neurocrine Biosciences, Inc. vs Bio-Techne Corporation: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: Dr. Reddy's Laboratories Limited vs Celldex Therapeutics, Inc.
Bio-Techne Corporation vs Exelixis, Inc.: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down Bio-Techne Corporation and ADMA Biologics, Inc.'s Expenses
Bio-Techne Corporation vs CRISPR Therapeutics AG: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: Bio-Techne Corporation vs Perrigo Company plc
Bio-Techne Corporation vs Xencor, Inc.: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down Corcept Therapeutics Incorporated and Celldex Therapeutics, Inc.'s Expenses
Cost of Revenue Trends: Alkermes plc vs Celldex Therapeutics, Inc.
Analyzing Cost of Revenue: PTC Therapeutics, Inc. and Celldex Therapeutics, Inc.
Cost of Revenue Trends: Perrigo Company plc vs Celldex Therapeutics, Inc.
Cost of Revenue Trends: Taro Pharmaceutical Industries Ltd. vs Celldex Therapeutics, Inc.